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a b s t r a c t
Stem cell transplantation affects patient's vulnerability to infections due to immunological changes
related to chemotherapy. Multiple myeloma is characterized by susceptibility to infections, and IL-6 and
TNF-α increased levels affect immune response (IR). Polymorphisms in promoter region of cytokine
genes may alter expression levels and affect IR. We performed interaction analysis of IL-6 (174G/C) and
TNF-α (308G/A) polymorphisms with infection susceptibility in 148 patients classiﬁed accordingly to
infection status and found an interaction when compared groups with and without bacteremia
(p¼0.0380). The interaction may be more important than single effects for the IR associated with the
infection susceptibility in ASCT.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Multiple myeloma (MM) is a plasma cell neoplasm character-
ized by the production of a monoclonal protein, bone destruction
and susceptibility to infections [1,2]. Most infections in myeloma
patients are caused by bacteria, and this susceptibility to infection is
mostly due to the reduction in the production of normal immu-
noglobulins, typical of the disease [3]. The conditioning regimen for
the autologous stem cell transplantation (ASCT) further increases
patient's vulnerability to infections [1].
High levels of proinﬂammatory cytokines such as IL-6 and TNF-α
are related to MM pathogenesis, and have a relationship with the
immune response and the susceptibility to infections. Single nucleo-
tide polymorphisms (SNPs) in the promoter region of cytokines genes
are responsible for altering their levels of expression, thereby affecting
the immune response [1,3,4]. Speciﬁcally, the SNP 174G4C
(rs1800795) has been correlated with higher levels of IL-6 [5], and
the 308G4A (rs1800629) is associated with higher serum levels of
soluble TNF-α [6]. These SNPs have been previously studied inmultiple
myeloma [4,6].
However, gene–gene interactions have been successfully used
to detect susceptibility to complex diseases, and it is possible that
gene interactions may inﬂuence the outcome in patients with
multiple myeloma [7,8]. Therefore, we aimed to evaluate the
association of these SNPs with bacteremia in MM patients sub-
mitted to ASCT. Moreover, as IL-6 and TNF-α cytokines are known
to biologically interact in immune response pathways, we also
performed gene–gene interaction analyses between these SNPs.
2. Material and methods
We studied 148 MM patients submitted to ASCT from the Bone
Marrow Transplantation unit of Federal University of Rio de
Janeiro, Rio de Janeiro, Brazil, from March 1997 to May 2007. The
study was approved by the Ethics Research Committee of the
Medicine School of Ribeirão Preto, University of São Paulo, and the
Federal University of Rio de Janeiro. Informed consent was
obtained from each individual.
All patients received melphalan-based conditioning regimen
and peripheral blood stem cells (PBSC) after mobilization with
granulocyte colony-stimulating factor (G-CSF) with or without
cyclophosphamide. Until 2006, no antibacterial prophylaxis had
been given. Since then, all patients received ciproﬂoxacin (500 mg
orally twice a day), started concomitantly with the conditioning
regimen, and was maintained until bone marrow recovery or
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fever. In case of fever, blood cultures were obtained, and the
patients were immediately started on intravenous cefepime Blood
cultures were repeated in case of persistent or recurrent fever, or
as clinically indicated. Modiﬁcations in the empirical antibiotic
regimen were performed according to the results of cultures and
the clinical course of the patient.
Genomic DNA was extracted from mobilized peripheral-blood
stem cells. Genotyping was carried out for the SNPs IL-6
(–174G4C) and TNF-α (–308G/A) using PCR followed by restriction
length fragment polymorphism (PCR-RFLP). Clinical and genotypic
database and genotypic analysis were performed with the Statistical
Package for the Social Sciences version 15 (SPSS Inc., Chicago, Ill),
using the Chi-square test. The gene–gene interaction analysis was
performed by multifactor dimensionality reduction (MDR) method
[8]. We used MDR to combine multilocus genotypes into high risk
and low risk cells, which were evaluated for the ability to predict
bacteremia through cross-validation and permutation testing. We
considered as the best model of interaction the one that had the
maximum testing accuracy and the maximum cross-validation
consistency (CVC). Permutation testing was performed to assess
the statistical signiﬁcance of the testing accuracy of the best model
[8]. Bivariate analysis (logístic regression) was performed to evalu-
ate the impact of the use of quinolones on the risk of bacteremia.
3. Results
We evaluated 148 MM patients, 87 women and 61 men, age
range 29–69 years, 58 of whom developed bacteremia during the
early post-transplant period (Table 1). The genotypes were in
Hardy–Weinberg equilibrium. We did not observe any statistically
signiﬁcant association between the genotypes of TNF-α and IL-6
polymorphisms and bacteremia (Table 2). However, analyzing the
association between bacteremia and the interaction of polymorph-
isms, we found a signiﬁcant interaction between TNF-α 308G4
A and IL-6 174G4C polymorphisms, with a CVC of 10/10 and
balanced accuracy of 0.6021 (p¼0.04). Using this method, we
could identify two risk groups: the high risk group comprised
patients with wild genotype of TNF-α 308G4A and mutated
genotype of IL-6 174G4C, wild genotype of TNF-α 308G4A
and heterozygous genotype of IL-6 174G4C, and heterozygous
for both genes (dark gray cells in Fig. 1). The low-risk group
comprised all other combinations (light gray cells in Fig. 1). As
shown in Table 3, the frequency of bacteremia overall (50.7% vs.
29.6%, p¼0.009) and of Gram-positive bacteremia (34.3% vs. 12.5%,
p¼0.002) was signiﬁcantly higher in the high risk group compared
with the low risk group.
We analyzed the impact of quinolone use on the frequency of
bacteremia. The frequency of bacteremia was signiﬁcantly lower in
patients receiving quinolone prophylaxis (16.7% vs. 43.5% in
patients not receiving quinolones, p¼0.01). We then run a
bivariate analysis to evaluate the inﬂuence of quinolone use and
the interaction of polymorphisms on the occurrence of bacteremia.
Receipt of quinolones decreased the risk of bacteremia (odds ratio
[OR] 0.25, 95% conﬁdence interval [95% CI] 0.08–0.81, p¼0.02)
while the high risk group (as deﬁned by the analysis of interaction
of polymorphisms) was associated with an increased risk of
bacteremia (OR 2.47, 95% CI 1.24–4.94, p¼0.01). Therefore, the
high risk group was associated with an increased risk of bacter-
emia independent of quinolone use.
Table 1
Characteristics of 148 patients with multiple myeloma undergoing autologous
hematopoietic cell transplantation.
Characteristic No.
Gender male: female 85: 63
Age (years), median (range) 54 (29–69)
Number of CD34 cells (106/kg), median (range) 3.89 (1.13–20.07)
Febrile neutropenia 147 (99.3%)
Duration (days) of neutropenia, median (range) 7 (3–25)
Duration (days) of antibiotic therapy, median (range)a 8 (1–44)
Quinolone prophylaxis 24 (16.2%)
Fluconazole prophylaxis 78 (52.7%)
Cefepime-based empiric antibiotic regimena 135/147 (91.8%)
In monotherapya 117/147 (79.6%)
Classiﬁcation of the febrile episodesa
Fever of unknown origin 70/147 (47.6%)
Bacteremia 58/147 (39.5%)
Gram-positive b 33b/58
Gram-negative b 28b/58
Polymicrobial b 4b/58b
Microbiologically documented without bacteremia 3/147 (2.0%)
Clinically documented 16 (10.9%)
a In 147 patients who developed febrile neutropenia.
b Within the 58 cases of bacteremia, 4 presented polymicrobial bacteremia.
Table 2
Genotype frequencies in patients with multiple myeloma and bacteremia due to Gram-positive or Gram-negative organisms.
TNF-α–308G4A IL-6–174G4C P value
N (%) N (%)
GG GA AA P value GG GC CC
Gram-negative bacteremia 23 (20.0) 5 (17.2) 0 0.58 17 (19.8) 10 (18.2) 1 (14.3) 0.92
Gram-positive bacteremia 25 (21.9) 8 (27.6) 0 0.45 18 (21.2) 12 (21.8) 3 (42.9) 0.41
All bacteremiasa 46 (40.0) 12 (41.4) 0 0.26 34 (39.5) 20 (36.4) 4 (57.1) 0.57
a The number of Gram-positive and Gram-negative bacteremia are higher than the number of total bacteremias because some patients had both Gram-positive and
Gram-negative bacteremia.
Fig. 1. Interaction model for TNF-α 308G4A and IL-6 174G4C polymorph-
isms when compared the groups with (left bars) and without bacteremia (right
bars), which are illustrated for each multilocus genotype combinations. The light
gray cells are labeled as low risk and the dark gray cells are labeled as high risk.
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4. Discussion
In the present study, we reported for the ﬁrst time the possible
association of TNF-α 308G4A and IL-6 174G4C genotypes
with bacteremia in MM patients submitted to ASCT. Interestingly,
these analyses suggest that the interaction of polymorphisms may
be more important than the effects of single polymorphisms for
the immune response associated with the susceptibility to infec-
tion in ASCT.
The patterns of high risk and low risk cells shown in Fig. 1 differ
across each of the different multilocus dimensions, which may be
interpreted as evidence of epistasis, or gene–gene interaction [8].
TNF-stimulates the secretion of IL-6 in bone marrow stromal cells
[9], which are associated with a worst prognosis in MM patients
[1]. The analysis of gene interaction efﬁciently discriminated two
risk groups, with very different incidences of bacteremia. Further-
more, the association of the interaction of polymorphisms and
bacteremia was still present after controlling for the use of
quinolones.
The present ﬁndings must be replicated in populations with
different genetic backgrounds. Moreover, as they focused only on
TNF-α and IL-6 polymorphisms, further studies should be con-
ducted to examine whether interactions between polymorphisms
in other genes may affect the infection status in MM patients.
Likewise, the association between these polymorphisms and
Gram-negative and Gram-positive bacteremia needs to be evalu-
ated in a larger number of patients.
4.1. Speculations
The present ﬁndings are relevant as they may contribute to the
search for genetic markers associated with infection in MM
patients submitted to ASCT, which may be potentially translate
into clinical application, with appropriate preventive measures for
high-risk patients.
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